XML 88 R77.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT AND GEOGRAPHIC INFORMATION - Segment Reporting Information (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Segment Reporting Information [Line Items]            
Total revenue, net $ 402,062,000   $ 380,834,000 $ 1,200,320,000 $ 1,167,881,000  
Cost of goods sold 195,071,000   180,596,000 589,565,000 534,892,000  
Research and development 22,456,000   27,435,000 74,181,000 84,167,000  
Selling, general & administrative 169,046,000   177,193,000 530,433,000 538,463,000  
Intangible asset amortization 3,728,000   3,760,000 11,186,000 17,575,000  
Goodwill impairment 0 $ 511,400,000 0 511,365,000 0 $ 0
Total costs and expenses 390,301,000   388,984,000 1,716,730,000 1,175,097,000  
Operating income (loss) 11,761,000   (8,150,000) (516,410,000) (7,216,000)  
Interest income 4,982,000   5,049,000 14,112,000 15,147,000  
Interest expense (22,725,000)   (19,373,000) (62,582,000) (51,648,000)  
Other income, net (842,000)   2,112,000 (2,932,000) 2,939,000  
Loss before income taxes (6,824,000)   (20,362,000) (567,812,000) (40,778,000)  
Codman Specialty Surgical            
Segment Reporting Information [Line Items]            
Total revenue, net 292,583,000   270,782,000 877,204,000 828,977,000  
Tissue Technologies            
Segment Reporting Information [Line Items]            
Total revenue, net 109,479,000   110,052,000 323,116,000 338,904,000  
Operating Segments | Codman Specialty Surgical            
Segment Reporting Information [Line Items]            
Total revenue, net 292,583,000   270,782,000 877,204,000 828,977,000  
Cost of goods sold 93,289,000   95,829,000 288,070,000 281,443,000  
Research and development 6,632,000   8,548,000 22,276,000 21,880,000  
Selling, general & administrative 62,433,000   65,867,000 201,309,000 157,483,000  
Intangible asset amortization 0   0 0 0  
Goodwill impairment 0     388,106,000    
Total costs and expenses 162,354,000   170,244,000 899,761,000 460,806,000  
Operating income (loss) 130,229,000   100,538,000 (22,557,000) 368,171,000  
Operating Segments | Tissue Technologies            
Segment Reporting Information [Line Items]            
Total revenue, net 109,479,000   110,052,000 323,116,000 338,904,000  
Cost of goods sold 42,668,000   40,529,000 138,499,000 119,512,000  
Research and development 4,189,000   4,506,000 12,243,000 13,858,000  
Selling, general & administrative 35,478,000   36,535,000 110,283,000 109,199,000  
Intangible asset amortization 0   0 0 0  
Goodwill impairment 0     123,259,000    
Total costs and expenses 82,335,000   81,570,000 384,284,000 242,569,000  
Operating income (loss) 27,144,000   28,482,000 (61,168,000) 96,335,000  
Corporate and Other            
Segment Reporting Information [Line Items]            
Total revenue, net 0   0 0 0  
Cost of goods sold 59,114,000   44,238,000 162,996,000 133,937,000  
Research and development 11,635,000   14,381,000 39,662,000 48,429,000  
Selling, general & administrative 71,135,000   74,791,000 218,841,000 271,781,000  
Intangible asset amortization 3,728,000   3,760,000 11,186,000 17,575,000  
Goodwill impairment 0     0    
Total costs and expenses 145,612,000   137,170,000 432,685,000 471,722,000  
Operating income (loss) $ (145,612,000)   $ (137,170,000) $ (432,685,000) $ (471,722,000)